Investigates minimal symptom expression as a key treatment goal in generalized myasthenia gravis, suggesting enhanced patient outcomes.
MSE, as a patient-centric endpoint, can be used alongside clinician-assessed measures and safety measures to support an integrated treatment goal that encompasses both efficacy and tolerability for the treatment of gMG. Future research should further define the clinical utility of MSE and sustained MSE and incorporate stakeholder input to validate MSE as a part of an integrated treatment goal in both clinical trials and real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Meisel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: